OECD's IL-2 Luc and IL-2 Luc LTT assays examine T-cell activation-related signaling and antimitotic effects in the same human reporter cell line. The guideline's evaluation includes medicines, but its overall performance figures combine drugs and other chemicals.
The Organisation for Economic Co-operation and Development (OECD) adopted Test Guideline 444A on June 25, 2025. OECD corrected the second sentence of paragraph 35 on July 2, 2026. The guideline describes a combined in vitro approach to identifying substances with potential immunosuppressive effects. This is a testing guideline, not an approval of an individual medicine or a claim that either assay can replace a full immune-safety assessment.
The two assays use 2H4 reporter cells derived from the human Jurkat T-cell line. IL-2 Luc measures a signal related to IL-2 production and T-cell activation. IL-2 Luc LTT adds information about antimitotic effects and cell proliferation. Results are interpreted separately, then combined: a positive immunosuppression result in either assay makes the combined in vitro classification positive.
The guideline describes an extended set of 83 substances: 46 pharmaceutical drugs and 37 other chemicals. The drug group includes anticancer agents, immunosuppressants with and without antimitotic effects, JAK inhibitors and non-immunosuppressive comparators. This gives the method a direct connection to medicine safety, while the reported overall classification figures still mix pharmaceutical and non-pharmaceutical substances.
Validation involved a lead laboratory and three independent laboratories under coordination by the Japanese Center for the Validation of Alternative Methods. For IL-2 Luc, reported within- and between-laboratory reproducibility were both 80.0% (4/5 and 16/20). For IL-2 Luc LTT, the corresponding values were 100.0% (15/15) and 92.0% (23/25). These denominators describe repeatability, not how well the assays identified a clinical risk.
Across 79 substances used for the combined reference-classification analysis, the guideline reports sensitivity of 88.7% (47/53) and specificity of 53.8% (14/26). After applying its stated domain considerations, sensitivity was 90.0% (45/50) and specificity remained 53.8% (14/26), across 76 substances. The higher detection rate comes with limited specificity; the figures cannot be read as drug-only clinical predictive accuracy.
The stimulation scheme bypasses some early T-cell receptor signals, and Jurkat-derived cells differ from normal T cells. Substances that require metabolic activation fall outside the model's stated domain. Highly hydrophobic compounds and direct interference with luciferase can also confound the signal. The guideline further says that neither assay can identify immunosuppressive effects of chemicals with a lowest observed effect level (LOEL) of 200 μg/L or higher under this test. OECD therefore frames the combination as one part of a wider immunotoxicity evaluation, with the two assays covering different mechanisms rather than providing a complete answer alone.
A new FDA draft describes how in vitro potency and safety data, anchored to clinical evidence, could support variants of individualized genome-editing therapeutics within a defined product boundary.
Australia’s TGA already considers non-animal evidence in therapeutic-goods assessment. Its October 2026 statement ties acceptance of a NAM to its intended use, human biological relevance, technical performance and reliability, with validation evidence scaled to the consequences of a wrong conclusion.
